In in vivo efficacy studies in colon carcinoma CT26 tumors, ExoASO STAT6 or C/EBPβ treatment results in a reduction in the expression of STAT6 and C/EBPβ in tumor‐associated CD11b+ myeloid cells. The gene discussed is CEBPB; the disease is neoplasm.